spls stock price

What stock symbol is SPLS?

What is Staples' stock symbol? Staples trades on the NASDAQ under the ticker symbol "SPLS."

How much is Staples stock today?

Staples, Inc. Share PriceBid Price10.25Ask Price10.26Volume0Last Trade-

How much is Tivo stock worth?

TIVO Price/Volume StatsCurrent price$6.0952-week highPrev. close$6.4152-week lowDay low$6.08VolumeDay high$6.42Avg. volume50-day MA$6.71Dividend yield1 more row

How much is a share of Barnes and Noble?

$2.8200$ 2.8500CloseChgChg %$2.82000.07002.55%

Is Staples stock a buy?

People buy staples in boom times and in bust times, which makes consumer staples stocks good performers no matter what's happening in the broader economy. That's why they're often considered defensive safe havens during a recession. Strong dividend income.

Who owns Staples now?

Sycamore PartnersStaples / Parent organizationSycamore Partners is a private equity firm based in New York specializing in retail and consumer investments. The firm has approximately $10 billion in aggregate committed capital. Wikipedia

What happened to my TiVo stock?

TiVo common stock previously traded under the ticker symbol TIVO and, as of June 1, is no longer listed for trading.

Should I buy Barnes and Noble stock?

Is Barnes & Noble Education Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NYSE: BNED) stock is to Buy BNED stock.

Will BNED stock go up?

Based on our forecasts, a long-term increase is expected, the "BNED" stock price prognosis for 2027-06-25 is 10.509 USD. With a 5-year investment, the revenue is expected to be around +256.25%. Your current $100 investment may be up to $356.25 in 2027.

Does Chick Fil A have stock?

Chick-fil-A is a private, family-owned company and does not offer stock options to the public. If you are interested in investing in Chick-fil-A by applying to become a franchised Owner/Operator, check our franchise page to learn more about opportunities in the U.S., Canada and Puerto Rico.

What are the best stocks to invest in?

Best Value StocksPrice ($)Market Cap ($B)Cleveland-Cliffs Inc. (CLF)16.488.6Azenta Inc. (AZTA)74.295.6eBay Inc. (EBAY)45.6725.62 more rows

When did Sycamore buy staples?

2017On Tuesday, Sycamore pulled off a $5.4 billion refinancing of Staples Inc., which it bought in 2017, that funded a staggering $1 billion dividend to the private equity firm.

Is TikTok on the stock market?

Knowing how to invest in stocks such as TikTok stock may not be obvious at first. TikTok is owned by ByteDance, which is not publicly traded. So, it isn't possible to buy shares of TikTok or ByteDance unless the company goes public.

Does Crayola have stock?

Crayola is owned by Hallmark Cards, Inc. Since Hallmark is a privately owned company, stock in both Crayola and Hallmark is privately held and unavailable for purchase. We are not listed on the stock exchange.

Is Staples a good dividend stock?

Staples(NASDAQ:SPLS) pays an annual dividend of $0.48 per share and currently has a dividend yield of 0.00%. View Staples' dividend history .

Who are Staples' key executives?

Staples' management team includes the following people: Robert E. Sulentic , Independent Chairman of the Board Shira D. Goodman , President, Chi...

Who are some of Staples' key competitors?

Some companies that are related to Staples include Tractor Supply (TSCO) , Ulta Beauty (ULTA) , Five Below (FIVE) , DICK'S Sporting Goods (DKS)...

What other stocks do shareholders of Staples own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Staples investors own include Ford Motor (F) , Twitter (T...

What is Staples' stock symbol?

Staples trades on the NASDAQ under the ticker symbol "SPLS."

What is Staples' stock price today?

One share of SPLS stock can currently be purchased for approximately $10.25.

How can I contact Staples?

Staples' mailing address is 500 Staples Dr, PO Box 9328, FRAMINGHAM, MA 01702-4478, United States . The official website for Staples is www.stapl...

What is the SLS call?

What is NPS in SELLAS?

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET. The call will be facilitated by SELLAS’ President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update. Event:Shareholder Update CallDate:Thursday, June 3, 2021Time:8:30 a.m. ETLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://www.sellaslifesciences.com/investors/events-and-presentations For interested individuals unable to join the conference call, a replay of the call will be available through June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13719788. The online archive of the webcast will be available at https://www.sellaslifesciences.com/investors/events-and-presentations after the conclusion of the call. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care. For more information on SELLAS, please visit www.sellaslifesciences.com. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. For more information, please contact: Investor Contacts Valter Pinto / Allison Soss KCSA Strategic Communications Email: [email protected] Phone: 914.907.2675 / 215.272.2707 Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications Email: [email protected] Phone: 212.896.1241 / 212.896.1276

What is the second product candidate for Sellas?

SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.